Mouse Tumor Models

IITRI is highly experienced with evaluating the efficacy of potential cancer therapeutics, including immuno-oncology biologics, using xenograft and syngeneic mouse tumor models for the National Cancer Institute (NCI) and other commercial organizations.

Xenograft models involve the transplantation of human cancer cells or solid tumors into an immunocompromised host mouse strain to avoid rejection of the cancer transplant. Because these tumors arise from actual human cancers, xenograft tumor models are thought to potentially more highly match the biological and genetic properties of the human cancer and provide data that will translate to human cancers in preclinical drug development studies.

In syngeneic models, tumor tissues that are derived from the same genetic background as the mouse strain are transplanted, avoiding rejection due to the common genetic identity. Since the host immune system is normal, the transplanted tumor may more closely represent a tumor's natural micro-environment in preclinical oncology in-vivo studies. However, there is the complicating factor of using a mouse and not a human tumor for efficacy studies of therapeutics intended for humans. These mouse tumor models can be used in cancer immunotherapy or cancer vaccine studies.

Xenograft Models

Disease Cell Line Mouse Strain
Lung cancer NCI-H522, NCI-H460, A549, NCI-H1975 Nude
Colorectal cancer COLO-205, HT29, HCT116, Caco-2, RKO Nude
Breast cancer MCF-7, T47D, MDA-MB-231 Nude, SCID
Prostate cancer PC-3, DU-145 Nude
Ovarian cancer OVCAR-3, OVCAR-5 Nude, SCID
Renal cancer RXF-393, CakI-1, A498 Nude
Melanoma cancer MDA-MB-435 Nude
Pancreatic cancer PANC-1 Nude
Liver cancer Hep G2 Nude

Syngeneic Models

Disease Cell Line Mouse Strain
Lung cancer Lewis Lung Cancer (LLC) C57BL/6
Colorectal cancer CT26 BALB/c
Breast cancer 4TI BALB/c
Melanoma cancer B16-F10 C57BL/6

Additional Efficacy Models

  • Cancer cell lines
  • Mouse mammary gland organ culture
  • Transgenic animal models
  • Chemical carcinogenesis
  • Inflammation-induced carcinogenesis
  • Precancerous legions


  • Tumor growth delay (latency, TGD)
  • Tumor growth inhibition (TGI)
  • IC50
  • Toxicity
  • Survival
  • Combination approaches

The IITRI Advantage

  • A highly experienced team of cancer biology scientists, with more than 250 publications
  • On-site bioanalytical laboratory for prompt analysis of preclinical samples
  • Personalized study design for standard, non-standard, and customized studies
  • Technical advisory and support regarding interpretation of study results

Related Services